About this trial
The study treatment is radiotherapy – different doses of radiotherapy will be given to patients. The first group of patients will receive the lowest dose (dose level 1) – this is the dose delivered to patients as standard of care. If the treatment does not cause serious side effects, it will be given to the next group of patients enrolled at a higher dose (dose level 2) – this is called ‘dose escalation’. If this higher dose of treatment does not cause serious side effects, the next group of patients will receive a higher dose (dose level 3). The doses will continue to increase for every group of patients, as long as no serious side effects occur. If this happens, the study is halted. Once the optimum dose level has been reached, a larger cohort of patients will all receive this dose.
Patient Profile
Patients with resectable or borderline resectable (per the National Comprehensive Cancer Network (NCCN) criteria) pancreatic adenocarcinoma.
Where’s this trial being run?
St Luke’s Radiation Oncology Network @ St Luke’s Hospital and St Vincents University Hospital
Can I join this study / trial?
The first step we recommend is to talk to your doctor or the cancer trials team at your hospital. You can find contact details for cancer trials research units in Ireland here.
It’s also a good idea to print this page and bring it with you to your appointment. It can help guide the conversation and remind you of what to ask. You may also want to talk to your family or friends about your options, as they can offer support as you make decisions.
For more detailed information
Click HereQuestions?
Here’s a list of questions you may have for your doctor or local cancer research team.
QuestionsSummary Data
| Name: | DP-IMRT Pancreas |
|---|---|
| Number: | 17-12 |
| Full Title: | Dose-Painted Intensity Modulated Radiotherapy Pancreas (DP-IMRT Pancreas): A non-randomised Phase I/II study of dose escalated hypofractionated Dose-Painted Intensity Modulated |
| Principal Investigator: | Dr Gerard McVey |
|---|---|
| Type: | In-House |
| Sponsor: | Cancer Trials Ireland |
| Recruitment Started: |
Global: January 2024 Ireland: January 2024 |
| Global Recruitment Target: | |
|---|---|
| Ireland Recruitment Target: | Phase I = minimum of 6, maximum of 18 patients. Phase II = 49 patients |